Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

119
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
119
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

191
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
191
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP-ddG: a unified structural paradigm with data efficacy and mixture-of-experts for predicting mutational effects on protein-protein interactions.

Bioinformatics (Oxford, England)·2026
Same author

A multi-modal co-attention model for accurate drug-target interaction prediction.

PloS one·2026
Same author

Association between urinary heavy metals, phthalates, phytoestrogens, and polycyclic aromatic hydrocarbons and endometriosis: A cross-sectional study from NHANES 1999 to 2016.

Medicine·2026
Same author

[Construction of a ubiquitination-related gene prognostic model for breast cancer based on taxane treatment response].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2026
Same author

Electrically Accelerated Mechanochemical Film Formation by a Phosphonium Phosphate Ionic Liquid: An <i>In Situ</i> Chemical Kinetics Investigation.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Asymmetric Drug-Drug Interaction Prediction Based on Generative Adversarial Networks and Knowledge Graph.

Journal of computational biology : a journal of computational molecular cell biology·2026

Related Experiment Video

Updated: Jan 1, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.5K

Overlap matrix completion for predicting drug-associated indications.

Mengyun Yang1,2, Huimin Luo1, Yaohang Li3

  • 1School of Computer Science and Engineering, Central South University, Changsha, Hunan, P.R. China.

Plos Computational Biology
|December 24, 2019
PubMed
Summary
This summary is machine-generated.

We developed overlap matrix completion (OMC2 and OMC3) to predict drug-associated indications by integrating diverse data. Our novel computational methods improve drug repositioning accuracy and identify promising new uses for existing drugs.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Related Experiment Videos

Last Updated: Jan 1, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Area of Science:

  • Computational biology
  • Pharmacology
  • Bioinformatics

Background:

  • Accurate identification of drug-associated indications is crucial for drug repositioning.
  • Existing computational methods for predicting drug-disease associations often struggle to integrate diverse prior information effectively.
  • Improving prediction precision requires novel approaches to incorporate multiple data types representing drug and disease characteristics.

Purpose of the Study:

  • To propose novel computational methods, overlap matrix completion for bilayer (OMC2) and tri-layer (OMC3) networks, for predicting potential drug-associated indications.
  • To effectively integrate multiple types of prior information to enhance the accuracy of drug-disease association predictions.
  • To validate the performance of OMC2 and OMC3 against state-of-the-art approaches in predicting drug indications.

Main Methods:

  • Developed overlap matrix completion (OMC) algorithms, specifically OMC2 for bilayer networks and OMC3 for tri-layer networks.
  • Constructed bilayer networks from drug- and disease-side aspects, obtaining block adjacency matrices.
  • Utilized OMC algorithms to complete missing entries in adjacency matrices and predict drug-disease association scores, exploiting low-rank structures.

Main Results:

  • OMC2 and OMC3 methods demonstrated effective prediction of potential drug-associated indications across various datasets.
  • Our methods achieved higher prediction accuracy compared to existing state-of-the-art approaches in 10-fold cross-validation.
  • De novo experiments and case studies confirmed the practical effectiveness of OMC methods in identifying promising drug indications.

Conclusions:

  • The proposed OMC2 and OMC3 methods offer a robust framework for predicting drug-disease associations by effectively integrating diverse prior information.
  • These computational approaches significantly improve prediction accuracy in drug repositioning tasks.
  • OMC methods provide a valuable tool for identifying novel therapeutic indications for existing drugs, supporting practical drug discovery efforts.